Emmaus Life Sciences to Participate in the 30th Piper Jaffray Healthcare Conference

TORRANCE, Calif.--(BUSINESS WIRE)-- Emmaus Life Sciences, Inc. (Emmaus), a leader in sickle cell disease treatment, announced today that its CEO, Yutaka Niihara, MD, MPH will present at the 30^th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 8:50 a.m. ET in New York, New York. A webcast of the event will be available at https://bit.ly/2P49yYl.

About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. Its lead product, Endari^TM (L-glutamine oral powder), demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia and has received U.S. FDA approval. Visit: http://www.emmausmedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005776/en/